# Oncimmune Holdings plc Appoint Bryan, Garnier & Co. and Berenberg as Joint Brokers

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-appoint-bryan-garnier-co-berenberg-joint-brokers/412740806
- Published: 2017-11-27T07:08:48+00:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT® platform technology today announces
it has appointed Bryan, Garnier & Co. and Berenberg as Joint Brokers in addition
to Zeus Capital, with immediate effect. Zeus Capital will continue to act as Nominated
Advisor to the Company.

Oncimmune Holdings plc is a leading early cancer detection company developing and
commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered
the development of autoantibody tests that can detect cancer up to four years earlier
than other methods and can be applied to a very wide range of solid tumour types.
The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test
in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT
®-Lung is available through physicians in the US and also privately in the UK and
other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial
for the early detection of lung cancer using biomarkers, the National Health Service(
NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver 
and ovarian cancer are in development.

Share on: